Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Novobiocin BA1116: Reliable Assay Workflows
2026-08-12
Learn how Novobiocin (SKU BA1116) can improve interpretation and execution of cell viability, proliferation, cytotoxicity, antiparasitic, and antimicrobial studies. This scenario-based guide connects mechanism, solvent compatibility, concentration selection, data interpretation, and practical product choice.
-
GSK343 EZH2 Inhibitor Workflows
2026-08-11
GSK343 enables controlled interrogation of EZH2-driven H3K27me3 repression, linking chromatin measurements to cancer-cell phenotypes. This practical guide combines dose planning, epigenetic readouts, APEX2–TERT assay choices, and troubleshooting for reproducible in vitro studies.
-
Anlotinib: Preclinical VEGFR2 Inhibition
2026-08-11
The reference study established anlotinib as a highly potent, orally active VEGFR2 inhibitor that suppresses tumor angiogenesis across biochemical, cellular, ex vivo, and animal models. Its strongest effects were observed in endothelial signaling and vascular growth, providing a mechanistic basis for interpreting anlotinib as an anti-angiogenic treatment candidate rather than simply a direct tumor-cell cytotoxin.
-
DNase I (RNase-free) for RNA Workflows
2026-08-10
Improve RNA extraction, RT-PCR, and in vitro transcription sample preparation by removing genomic DNA without introducing RNase activity. This workflow also shows how controlled DNA digestion can support organoid–fibroblast assays while preserving a clear boundary between validated product use and experimental adaptation.
-
Cy5 TSA Fluorescence System Kit for Astrocytes
2026-08-09
Discover how the Cy5 TSA Fluorescence System Kit can convert astrocyte atlas discoveries into spatially resolved protein and RNA validation. This guide connects tyramide chemistry with assay design, controls, microscopy, and developmental neurobiology.
-
NADH Potentiates Aminoglycosides Against E. tarda
2026-08-08
A 2024 study found that exogenous NADH reprogrammed Edwardsiella tarda metabolism, increased ATP production, and enhanced the bactericidal activity of neomycin and other antibiotic classes. The work supports metabolic co-treatment as a strategy for lowering antibiotic requirements, while highlighting the need for validation across strains, dosing conditions, and infection models.
-
Lumiracoxib Workflows for COX-2 Research
2026-08-07
Lumiracoxib enables time-resolved investigation of COX-2 signaling in inflammation, ischemia, angiogenesis, and skeletal muscle repair. This workflow-focused guide shows how to pair selective inhibition with prostaglandin, VEGF, MMP, and vascular readouts while avoiding common solubility and interpretation errors.
-
Baicalein for Cancer and Inflammation: Advanced Protocols &
2026-08-07
Baicalein (5,6,7-trihydroxy-2-phenylchromen-4-one) empowers researchers with precision inhibition of the 12-LOX pathway, enabling nuanced studies of cancer proliferation and inflammatory signaling. This guide delivers actionable protocols, troubleshooting strategies, and comparative insights to maximize impact with APExBIO’s high-purity Baicalein.
-
Pam3CSK4 TFA: Strategic Leverage in Translational TLR1/2 Res
2026-08-06
This thought-leadership article explores how Pam3CSK4 TFA, a synthetic TLR1/2 agonist, empowers translational researchers to interrogate maternal-neonatal immunity, with a focus on biomarker-driven risk stratification for Group B Streptococcus (GBS) in pregnancy. Mechanistic insights, protocol considerations, and competitive positioning are integrated alongside actionable guidance for translational immunology teams.
-
Age-Related CMA Decline Drives Skeletal Muscle Myopathy
2026-08-06
This study identifies a progressive loss of chaperone-mediated autophagy (CMA) activity in skeletal muscle as a key driver of age-associated myopathy. The work demonstrates mechanistic links between CMA decline, impaired mitochondrial protein turnover, and muscle dysfunction, providing new insight for researchers investigating proteostasis and muscle aging.
-
Lactate-GPR81/FARP1 Axis Enables Insulin-Independent Glucose
2026-08-05
This study uncovers a novel lactate-activated GPR81/FARP1 signaling axis that drives insulin-independent glucose uptake in skeletal muscle by promoting GLUT4 translocation via RAC1 activation. These findings highlight a metabolic pathway that operates parallel to insulin signaling, with implications for new strategies in glycemic control and metabolic disease intervention.
-
Ferrocenyl Novobiocin Derivatives: Synthesis and Bioactivity
2026-08-05
This study synthesized and evaluated novel ferrocenyl and organic novobiocin derivatives for activity against Plasmodium falciparum and breast cancer cells. The incorporation of a ferrocene moiety enhanced biological activity, highlighting new avenues for overcoming drug resistance in antimalarial and anticancer research.
-
Midecamycin: Applied Protocols for Gram-Positive Bacteria In
2026-08-04
Midecamycin stands out as an acetoxy-substituted macrolide antibiotic with precise utility in Gram-positive bacterial inhibition and protein synthesis assays. This article provides actionable protocols, troubleshooting strategies, and comparative insights to boost reproducibility and data clarity in advanced microbiology research.
-
Carvacrol: Redox Modulation and Translational Value in Cell
2026-08-04
Explore Carvacrol (5-isopropyl-2-methylphenol) as a unique redox modulator for advanced cell cycle and apoptosis research. This article reveals new translational insights, practical assay strategies, and mechanistic depth not found in standard guides.
-
Practical Use of HyperScribe™ T7 High Yield Cy3 RNA Labeling
2026-08-03
The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus enables efficient synthesis of randomly Cy3-labeled RNA probes for applications such as in situ hybridization and Northern blot analysis. It addresses challenges in probe yield and labeling uniformity for sensitive RNA detection workflows, but is not suitable for diagnostic, clinical, or therapeutic use.